| Followers | 238 |
| Posts | 15468 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Tuesday, March 22, 2022 2:15:52 PM
Thanks for posting those past links of yours. The BATON system is interesting, but I'll admit, I don't quite understand how the system works, or would be applied in the treatment process. DCs carry antigens, not T cells... rather, they carry the antigens to the T cells, which activates them.
I'm curious how this system would work. It doesn't load the DCs with T cells, but with neoantigens? As I see it, if a tumor that's been removed and flash frozen had neoantigens on it, and DCVax-L is made from that, the vaccine, as it is made now, is loaded with those same Neo antigens.
And if Direct is used, and injected into a tumor with "neoantigens" (neoantigens being antigens that cannot be recognized as "self" - I believe? - that's perhaps, too simple an explanation), then the injected DCs will also pick up the neoantigens and antigens present in that particular tumor and run back to the T cells carrying those to again, activate those T cells.
So I'm curious if there is a moderately simple explanation that anyone can provide as to how this BATON system might work?
I'm curious how this system would work. It doesn't load the DCs with T cells, but with neoantigens? As I see it, if a tumor that's been removed and flash frozen had neoantigens on it, and DCVax-L is made from that, the vaccine, as it is made now, is loaded with those same Neo antigens.
And if Direct is used, and injected into a tumor with "neoantigens" (neoantigens being antigens that cannot be recognized as "self" - I believe? - that's perhaps, too simple an explanation), then the injected DCs will also pick up the neoantigens and antigens present in that particular tumor and run back to the T cells carrying those to again, activate those T cells.
So I'm curious if there is a moderately simple explanation that anyone can provide as to how this BATON system might work?
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
